Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after mri-guided prostate biopsy-A pilot study

Anticancer Research

Volumn 34, Issue 5, 2014, Pages 2459-2466

  Arsov, Christian ^a   Jankowiak, Frank ^b   Hiester, Andreas ^a   Rabenalt, Robert ^a   Quentin, Michael ^a   Schimmöller, Lars ^a   Blondin, Dirk ^a   Antoch, Gerald ^a   Albers, Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Department of Pathology ^*  (Austria)

Author keywords

Active surveillance; CCP score; Cell cycle progression score; MRI guided biopsy; Multiparametric MRI; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER OF THE PROSTATE RISK ASSESSMENT SCORE; CANCER PROGNOSIS; CELL CYCLE PROGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; GLEASON SCORE; HOUSEKEEPING GENE; HUMAN; MALE; MIDDLE AGED; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; QUALITATIVE RESEARCH; TRANSRECTAL ULTRASONOGRAPHY; ACTIVE SURVEILLANCE; BIOPSY; CANCER STAGING; CCP SCORE; CELL CYCLE; CELL-CYCLE PROGRESSION SCORE; GENETICS; METHODOLOGY; MRI-GUIDED BIOPSY; MULTIPARAMETRIC MRI; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; WATCHFUL WAITING;

ACTIVE SURVEILLANCE; CCP SCORE; CELL-CYCLE PROGRESSION SCORE; MRI-GUIDED BIOPSY; MULTIPARAMETRIC MRI; PROSTATE CANCER;

AGED; BIOPSY; CELL CYCLE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; PROSTATIC NEOPLASMS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; WATCHFUL WAITING;

EID: 84902997681     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH and Roobol MJ: Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63: 597-603, 2013.
2. Klotz L, Zhang L, Lam A, Nam R, Mamedov A and Loblaw A: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28: 126-131, 2010.
3. Park BH, Jeon HG, Choo SH, Jeong BC, Seo SI, Jeon SS, Choi HY and Lee HM: Role of multiparametric 3.0 tesla magnetic resonance imaging in prostate cancer patients eligible for active surveillance. BJU Int, 2013 Aug 23. [Epub ahead of print].
4. Stamatakis L, Siddiqui MM, Nix JW, Logan J, Rais-Bahrami S, Walton-Diaz A, Hoang AN, Vourganti S, Truong H, Shuch B, Parnes HL, Turkbey B, Choyke PL, Wood BJ, Simon RM and Pinto PA: Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer 119: 3359-3366, 2013.
5. Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A, Nicolaiew N, Terry S, Allory Y, Loric S, Salomon L, Vacherot F and de la Taille A: Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 59: 422-429, 2011.
6. Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT and Nelson PS: Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 19: 2442-2450, 2013.
7. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, Møller H, Scardino P, Warren JD, Park J, Younus A, Flake DD 2nd, Wagner S, Gutin A, Lanchbury JS and Stone S: Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12: 245-255, 2011.
8. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S and Carroll PR: Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 31: 1428-1434, 2013.
9. Freedland SJ, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Gutin A, Sangale Z, Lanchbury JS, Salama JK and Stone S: Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 86: 848-853, 2013.
10. Cuzick J, Berney DM, Fisher G, Mesher D, Møller H, Reid JE, Perry M, Park J, Younus A, Gutin A, Foster CS, Scardino P, Lanchbury JS and Stone S: Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106: 1095-1099, 2012.
11. Arsov C, Blondin D, Rabenalt R, Antoch G, Albers P and Quentin M: Standardised scoring of a multi-parametric 3-T MRI for a targeted MRI-guided prostate biopsy. Urologe A 51: 848-856, 2012.
12. Schimmöller L, Quentin M, Arsov C, Lanzman RS, Hiester A, Rabenalt R, Antoch G, Albers P and Blondin D: Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard. Eur Radiol 23: 3185-3190, 2013.
13. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V and Fütterer JJ: ESUR prostate MR guidelines 2012. Eur Radiol 22: 746-757, 2012.
14. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J and Emberton M: Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59: 477-494, 2011.
15. Röthke M, Blondin D, Schlemmer HP and Franiel T. PI-RADS classification: structured reporting for MRI of the prostate. Rofo 185: 253-261, 2013.
16. Cooperberg MR, Carroll PR and Klotz L: Active surveillance for prostate cancer: progress and promise. J Clin Oncol 29: 3669-3676, 2011.
17. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C and Soloway MS: Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 62: 976-983, 2012.
18. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA and Guillonneau BD: Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 180: 1964-1967, 2008.
19. Suardi N, Briganti A, Gallina A, Salonia A, Karakiewicz PI, Capitanio U, Freschi M, Cestari A, Guazzoni G, Rigatti P and Montorsi F: Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. BJU Int 105: 1548-1552, 2010.
20. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J and Carroll PR: Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 181: 1628-1633, 2009.
21. Berg KD, Toft BG, Røder MA, Brasso K, Vainer B and Iversen P: Prostate needle biopsies: interobserver variation and clinical consequences of histopathological re-evaluation. APMIS 119: 239-246, 2011.
22. McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR and Brooks JD: The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol 186: 465-469, 2011.
23. Taylor JA 3rd, Gancarczyk KJ, Fant GV and Mcleod DG: Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer. Urology 60: 841-845, 2002.
24. Thompson J, Lawrentschuk N, Frydenberg M, Thompson L and Stricker P: The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Int 112(Suppl 2): 6-20, 2013.
25. Park BH, Jeon HG, Choo SH, Jeong BC, Seo SI, Jeon SS, Choi HY and Lee HM: Role of multiparametric 3.0 tesla magnetic resonance imaging in prostate cancer patients eligible for active surveillance. BJU Int, 2013 Aug 23. [Epub ahead of print].
26. Mullins JK, Bonekamp D, Landis P, Begum H, Partin AW, Epstein JI, Carter HB and Macura KJ: Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int 111: 1037-1045, 2013.